Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.35 |
| ▸ | KDM5A | P29375 | 3/20 | 0.35 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.35 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.35 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 3/20 | 0.34 |
| ▸ | CES1 | P23141 | 3/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29055799 | 0.84 | FAAH (0.44) | EPHX1DNM1KDM5APHF8KDM4C | |
| SCHEMBL7684377 | 0.80 | EPHX1 (0.47) | EPHX1DNM1ZDHHC20ZDHHC2EPHX2 | |
| SCHEMBL10925540 | 0.79 | DNM1 (0.39) | DNM1ZDHHC20ZDHHC2CES2CES1 | |
| SCHEMBL1401294 | 0.79 | GPR84 (0.41) | DNM1ZDHHC20EPHX2 | |
| SCHEMBL1400991 | 0.76 | AKR1B1 (0.39) | DNM1KDM5AKDM4CZDHHC20EPHX2 | |
| SCHEMBL7674452 | 0.76 | FAAH (0.50) | DNM1ZDHHC20ZDHHC2EPHX2 | |
| SCHEMBL8614628 | 0.76 | PLA2G2A (0.38) | EPHX1 | |
| SCHEMBL965001 | 0.76 | — | — | |
| SCHEMBL7686630 | 0.75 | CES2 (0.34) | EPHX1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL9781921 | 0.75 | KDM5A (0.45) | EPHX1S1PR2S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7867992-B2 | such as 1-Cyclopropyl-N-(2,4-dichlorobenzyl)-6-fluoro-8-methoxy-7-[3-methyl-4-(2-{[(methylamino)carbonyl]amino}-2-oxoethyl)piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxamide, used for the treatment and/or prophylaxis of viral diseases or infections, particularly against cytomegaloviruses | AICURIS GMBH & CO. KG (DE) | 2011-01-11 | — | — | US | disclosed |
| US-20070293478-A1 | Substituted quinolones | BAYER HEALTHCARE AG (DE) | 2007-12-20 | — | — | US | disclosed |
| EP-1768973-B1 | SUBSTITUTED QUINOLONES | AICURIS GMBH & CO KG (DE) | 2007-12-05 | — | — | EP | disclosed |
| EP-1768973-A1 | SUBSTITUTED QUINOLONES | AiCuris GmbH & Co. KG (DE) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006008046-A1 | SUBSTITUTED QUINOLONES | AICURIS GMBH & CO. KG (DE) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293478-A1 | Substituted quinolones | IRF3, TPMT, NQO2 | EPHX1 1620/4885S1PR2 4566/4885S1PR1 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.